US Single Photon Emission Computed Tomography (SPECT) Market in News Form (April 26, 2025)

US SPECT Market Shows Steady Growth, Driven by Aging Population and Chronic Disease Prevalence

The US market for Single Photon Emission Computed Tomography (SPECT) continues on a stable growth trajectory, fueled by the increasing prevalence of chronic diseases, particularly cardiovascular and neurological disorders, and a growing elderly population. Recent market analyses indicate a consistent demand for this crucial diagnostic imaging modality.

Key Market Trends and Developments:

• Market Size and Growth Projections: While specific 2025 figures are still being compiled, projections from late 2024 and early 2025 consistently point towards a market expansion. One report estimated the global SPECT market to reach USD 4.76 billion by 2032, with the US holding a significant share. Another analysis projected the US SPECT market to reach USD 10.66 billion by 2034, demonstrating a robust Compound Annual Growth Rate (CAGR) of around 15.7% from 2025. More conservative estimates still predict a healthy CAGR of around 4-6% in the coming years.   
• Dominance of Hybrid SPECT/CT Systems: Hybrid SPECT/CT systems are increasingly becoming the standard of care in the US. These systems combine the functional imaging capabilities of SPECT with the detailed anatomical information provided by Computed Tomography (CT), leading to more accurate diagnoses, improved localization of abnormalities, and enhanced treatment planning, particularly in oncology and cardiology.   
• AI and Machine Learning Integration: A significant trend gaining traction in the US SPECT market is the integration of Artificial Intelligence (AI) and Machine Learning (ML) algorithms. These technologies are being implemented to enhance image reconstruction, reduce noise, improve diagnostic accuracy, and streamline workflows for radiologists.   
• Advancements in Radiopharmaceuticals: Continuous innovation in radiopharmaceuticals is expanding the clinical applications of SPECT. The development of more specific and efficient tracers allows for better targeting of specific tissues and disease processes, improving diagnostic precision and patient outcomes.   
• Cardiology and Neurology Remain Key Application Areas: SPECT continues to be a vital tool in diagnosing and managing cardiovascular diseases, such as coronary artery disease and assessing myocardial perfusion. In neurology, SPECT scans aid in the diagnosis of stroke, seizures, Parkinson's disease, dementia, and traumatic brain injuries.   
• Growing Role in Oncology: SPECT, particularly SPECT/CT, plays an increasingly important role in oncology for cancer detection, staging, monitoring treatment response, and guiding targeted therapies. The ability of SPECT to identify areas of high metabolic activity, often indicative of tumors, makes it invaluable in cancer management.   
• Focus on Technological Improvements: Manufacturers are continuously developing SPECT systems with enhanced features such as faster acquisition times, higher resolution detectors, improved software interfaces, and more compact designs for specialized applications.
• Cost Considerations and Accessibility: While SPECT is generally more affordable than Positron Emission Tomography (PET) scans, the cost of the technology and radiopharmaceuticals remains a factor influencing accessibility in some healthcare settings. Efforts to improve cost-effectiveness and wider availability are ongoing.   

Recent News and Developments:

• FDA Approval for Cardiovascular Imaging System: In September 2024, the FDA approved SpectraWAVE's HyperVue cardiovascular imaging system, highlighting the ongoing advancements in SPECT technology for cardiac applications.
• Investment in Radiopharmaceutical Manufacturing: Jubilant Radiopharma announced plans in June 2024 to invest significantly in expanding its PET radiopharmaceutical manufacturing capacity across the US. While focused on PET, this underscores the broader growth and investment in the nuclear medicine sector, which includes SPECT.  
• New SPECT/CT System Launches: Companies like Siemens Healthineers and GE Healthcare continue to introduce advanced SPECT/CT systems with enhanced capabilities, such as the Symbia Pro.specta and Discovery NM/CT series, reflecting the market's demand for hybrid imaging solutions.   

In Conclusion:

The US SPECT market is demonstrating consistent growth, driven by its established clinical utility, technological advancements, and the increasing need for effective diagnostic imaging in an aging population with a rising prevalence of chronic diseases. The integration of AI, the development of novel radiopharmaceuticals, and the continued adoption of hybrid SPECT/CT systems are shaping the future of this important medical imaging modality, promising improved diagnostic accuracy and better patient care across various clinical specialties